Medina-Herrera, A.
Vazquez, I.
Cuenca, I.
Rosa-Rosa, J. M.
Ariceta, B. http://orcid.org/0000-0001-8819-402X
Jimenez, C.
Fernandez-Mercado, M.
Larrayoz, M. J.
Gutierrez, N. C.
Fernandez-Guijarro, M.
Gonzalez-Calle, V. http://orcid.org/0000-0002-5493-6707
Rodriguez-Otero, P. http://orcid.org/0000-0001-5236-7785
Oriol, A.
Rosiñol, L. http://orcid.org/0000-0002-2534-9239
Alegre, A.
Escalante, F.
De La Rubia, J. http://orcid.org/0000-0002-8354-768X
Teruel, A. I.
De Arriba, F. http://orcid.org/0000-0002-4451-1318
Hernandez, M. T. http://orcid.org/0000-0002-6576-7881
Lopez-Jimenez, J. http://orcid.org/0000-0002-2969-3002
Ocio, E. M.
Puig, N.
Paiva, B. http://orcid.org/0000-0003-1977-3815
Lahuerta, J. J. http://orcid.org/0000-0002-3393-9570
Bladé, J. http://orcid.org/0000-0002-4563-3405
San Miguel, J. F. http://orcid.org/0000-0002-9183-4857
Mateos, M. V. http://orcid.org/0000-0003-2390-1218
Martinez-Lopez, J. http://orcid.org/0000-0001-7908-0063
Calasanz, M. J. http://orcid.org/0000-0002-0374-3008
Garcia-Sanz, R. http://orcid.org/0000-0003-4120-2787
Gonzalez-Calle, V.
De La Rubia, J.
De Arriba, F.
Rios, R.
Sureda, A.
Blanchard, M. J.
Martinez-Martinez, R.
Moraleda, J. M.
Bargay, J.
Gironella, M.
Palomera, L.
Gonzalez-Montes, Y.
Martí, J. M.
Krsnik, I.
Arguiñano, J. M.
Gonzalez, M. E.
Gonzalez, A. P.
Casado, L. F.
,
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PMP21/00015)
Article History
Received: 9 November 2023
Revised: 9 April 2024
Accepted: 12 April 2024
First Online: 29 April 2024
Competing interests
: The authors report personal fees from, or have consulted or served in an advisory role for Janssen (AMH, MVM, PRO, VGC, AO, LR, AA, JDLR, FDA, BP, EMO, JJL, JFSM, JML, MJC, RGS), BMS-Celgene (MVM, PRO, VGC, AO, LR, AA, JDLR, FDA, BP, EMO, JJL, JFSM, JML, MJC, RGS), Amgen (MVM, PRO, VGC, AO, LR, AA, JDLR, FDA, BP, EMO, JJL, JFSM, MJC), Takeda (MVM, AO, LR, AA, JDLR, PRO, BP, EMO, JJL, JFSM, RGS), Sanofi (MVM, AA, PRO, JDLR, FDA, BP, EMO, JJL, JFSM), GSK (MVM, PRO, AA, JDLR, FDA, EMO, BP, JFSM), Oncopeptides (MVM, AA, PRO, EMO), Regeneron (AA, EMO, MVM, PRO, JFSM), MSD (EMO, JFSM), AbbVie (EMO, PRO, MVM, JFSM), Pfizer (AA, EMO, PRO, JDLR, MVM), Roche (MVM, BP, JFSM), Karyopharm (JDLR, EMO, JFSM), Secura-Bio (EMO, JFSM), Novartis (JFSM, JML, MJC), Adaptive Biotechnologies (BP, MVM), Beckton-Dickinson (BP), Menarini-Stemline (EMO), Creative BioLabs (BP), H3 Biomedicine (PRO), Invivoscribe (AMH), Sea-Gen (MVM), Blue-Bird bio (MVM), Hospira (RGS), Pharmacyclics (RGS), Gilead (PRO, RGS) and Incyte (RGS).